Breaking News

Johnson & Johnson Agrees to Acquire Intra-Cellular Therapies

Adds Intra-Cellular Therapies’ CAPLYTA, a once-daily oral therapy approved to treat adults with schizophrenia, to its portfolio.

Author Image

By: Charlie Sternberg

Associate Editor

Johnson & Johnson has agreed to acquire all outstanding shares of Intra-Cellular Therapies Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6 billion. “Building on our nearly 70-year legacy in neuroscience, this unique opportunity to add Intra-Cellular Therapies to our Innovative Medicine business demonstrates our commitm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics